MGB Biopharma
1 known investors
MGB Biopharma develops a new class of anti-infective small-molecule drugs based on Minor Groove Binder (MGB) compounds, targeting susceptible and resistant bacterial infections. Its lead candidate, MGB-BP-3, is in clinical development for Clostridium difficile-associated diarrhea (CDAD).
Investors Β· 1
Frequently asked questions
- What does MGB Biopharma do?
- MGB Biopharma develops a new class of anti-infective small-molecule drugs based on Minor Groove Binder (MGB) compounds, targeting susceptible and resistant bacterial infections. Its lead candidate, MGB-BP-3, is in clinical development for Clostridium difficile-associated diarrhea (CDAD).
- Who are MGB Biopharma's investors?
- MGB Biopharma's investors include Archangels.